KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Income (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Net Income for 10 consecutive years, with $470.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income rose 270.29% year-over-year to $470.0 million, compared with a TTM value of $1.5 billion through Dec 2025, up 178.52%, and an annual FY2025 reading of $1.4 billion, up 171.58% over the prior year.
  • Net Income was $470.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from $646.0 million in the prior quarter.
  • Across five years, Net Income topped out at $646.0 million in Q3 2025 and bottomed at -$1.3 billion in Q4 2022.
  • Average Net Income over 5 years is -$156.8 million, with a median of -$46.0 million recorded in 2021.
  • The sharpest move saw Net Income surged 294.34% in 2021, then crashed 1286.59% in 2022.
  • Year by year, Net Income stood at -$151.0 million in 2021, then crashed by 783.44% to -$1.3 billion in 2022, then surged by 132.38% to $432.0 million in 2023, then tumbled by 163.89% to -$276.0 million in 2024, then soared by 270.29% to $470.0 million in 2025.
  • Business Quant data shows Net Income for TEVA at $470.0 million in Q4 2025, $646.0 million in Q3 2025, and $203.0 million in Q2 2025.